Shanghai RAAS has continuously received a Wind ESG AA rating, with a comprehensive score of 8.70同壁财经·Jun 5 at 05:50 AM002252-0.77%
Shanghai RAAS: Executives have increased their holdings by 0.014% of sharesZhitong·Oct 31, 2025 at 04:18 AM002252-0.77%
Shanghai RAAS: The net profit for the third quarter was 441 million yuan, a decrease of 26.16%Zhitong·Oct 27, 2025 at 05:28 AM002252-0.77%
Shanghai RAAS's controlling shareholder Haiyingkang has completed an increase in holdings, with a total investment amount of approximately 500 million yuanZhitong·Sep 15, 2025 at 04:31 AM002252-0.77%
Shanghai RAAS: Executives plan to increase holdings by 6 million yuanZhitong·Sep 4, 2025 at 05:59 AM002252-0.77%
Shanghai RAAS: Cumulatively repurchased 1.03% of the company's sharesZhitong·Sep 2, 2025 at 07:19 AM002252-0.77%
Shanghai RAAS: Net profit of 1.03 billion yuan in the first half of 2025, a year-on-year decrease of 17.00%Zhitong·Aug 29, 2025 at 07:52 AM002252-0.77%
Shanghai RAAS: Application for new clinical trial indications for SR604 injection has been acceptedZhitong·Aug 25, 2025 at 05:17 AM002252-0.77%
Shanghai RAAS: The controlling shareholder increased their stake by 0.40% after half of the termZhitong·Aug 21, 2025 at 04:40 AM002252-0.77%
Shanghai RAAS: Plans to appoint Ernst & Young Hua Ming as the accounting firm for 2025, previously KPMG HuazhenZhitong·Jul 15, 2025 at 07:04 PM002252-0.77%
Shanghai RAAS: SR604 injection enters Phase IIb clinical trial researchZhitong·Jul 8, 2025 at 05:11 AM002252-0.77%
Shanghai RAAS today conducted a block trade at a discount, with 68.1766 million shares traded, totaling a transaction amount of 468 million yuanZhitong·Jun 25, 2025 at 04:17 AM002252-0.77%
Shanghai RAAS's controlling shareholder plans to increase its stake in the company by 250 million to 500 million yuanZhitong·May 21, 2025 at 04:26 AM002252-0.77%
